Macitentan is used to treat pulmonary arterial hypertension. It is an endothelin receptor antagonist (ERA) that lowers the pressure in the pulmonary arteries (blood vessels in the lungs that transfer oxygen into the blood) by blocking the effects of endothelin. It may have the potential to reverse some of the damage done by the condition. This should also improve symptoms such as breathlessness and increase your ability to exercise.
This medication may also be used for other conditions as determined by your doctor.
Common side effects include:
These side effects may be minimised by starting with a lower dose and may improve or go away with time. Inform your healthcare professional if it becomes bothersome or does not go away.
Rare but serious side effects include:
These side-effects are usually not significant, they are often treatable once detected early. You will need frequent blood tests to monitor for them.
The symptoms of a drug allergy include one or more of the following:
If you experience any of these symptoms, you should stop your medication and see your healthcare professional immediately.
Inform your healthcare professional if:
Avoid taking grapefruit when you are taking this medicine as grapefruit may interact with your medicine and increase the risk of side-effects.
Some medications may interact with Macitentan and affect their effectiveness or increase the risk of side effects. However, these medications may also be important for your treatment. Inform your healthcare professional of the other medications you are currently taking. Examples include:
Consult your healthcare professional if you are unsure whether your existing medications can be taken together with this medication.
If you forget to take a dose, take it as soon as you remember. If it is almost time for your next dose, skip the missed dose. Then take your next dose at the usual time. Do not take two doses to make up for the missed dose.
Pack this medication into a black trash bag and seal it tightly before throwing into the rubbish chute or bin.
Subscribe to our mailing list to get the updates to your inbox